Historical Review of Glasses Used for Parenteral Packaging

Pharmaceutical Technologies | Corning Incorporated | June 09, 2020Corning Incorporated (NYSE: GLW) today announced it will receive $204 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services through its partnership with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and ...

Corning Incorporated owns two pharmaceutical glass tubing subsidiaries: Corning PharmaceuticalGlass, LLC in Vineland, NJ (USA) and Corning Pharmaceutical Glass S.p.A. in Pisa, Italy. With over160 years of experience in specialty glass and materials science innovation, Corning PharmaceuticalGlass is uniquely suited to supply high-quality clear and amberborosilicate glass tubing for pharmaceutical primary packaging.

Valor® Glass Product Information Brochure

An overview of Valor Glass pharmaceutical packaging solution that includes technical data, performance data and Corning capabilities and services.

A capabilities brochure for CPG tubing offerings and services

Chemical and Physical Characteristics for Corning® 51-C Clear Borosilicate Glass Tubingwith Cerium for Gamma Sterilization

Chemical and Physical Characteristics for Corning® 51-V Clear Borosilicate Glass Tubing

Chemical and Physical Characteristics for Corning® 51-L Amber Borosilicate Glass Tubing

Chemical and Physical Characteristics for Corning® 51-D Clear Borosilicate Glass Tubing

Chemical and Physical Characteristics for Corning® 51-A Amber Borosilicate Glass Tubing

Chemical and Physical Characteristics for Corning® 33 Clear Borosilicate Glass Tubing

Chemical and Physical Characteristics for Valor® Glass

Chemical and Physical Characteristics for Valor®️ Glass

51-C Tubing Datasheet

 Conventional Pharmaceutical Glass vs. Corning Valor® Glass

Comparison of delaminated flakes from a borosilicate container and absence of delamination in Corning Valor® Glass. An accelerated lamellae formation (ALF) technique, first published in The PDA Journal (2014) by C. Sloey, C. Gleason and J. Phillips was used to produce the delaminated borosilicate glass flakes in this video.

Comparison of converting process for pharmaceutical primary glass packaging. Sodium-borate evaporates out of borosilicate glass container during converting, producing heterogenous areas that are predisposed to delaminate. Corning Valor® Glass eliminates delamination. Sodium-borate evaporation is not possible. As a result, Valor Glass containers have a uniform, chemically durable drug contacting surface.

In addition to eliminating delamination and dramatically reducing the probability of cracks, breaks and the risk of contamination by glass particles, Valor® enables smoother filling operations. Use of Valor® containers reduces line interventions, enabling lines to run at much higher speeds with improved yields. This results in more reliable access to medicines for patients around the world.

The package for purity: Valor® containers are extremely damage resistant and significantly reduce particle generation. Valor™ containers have demonstrated up to a 96% reduction in peak particle counts on commercial filling lines, substantially reducing risk of particulate contamination.

There are four steps from the formation of a heterogeneity to delamination for borosilicate glass packaging. Corning notes those steps include, 1) Formation of heterogeneity, 2) Leaching, 3) Swelling and 4) Spalling off a delaminated flake. Corning Valor® Glass is a boron-free glass package designed specifically for pharmaceutical use to eliminate delamination. Valor Glass has uniform surface chemistry and does not form boron-rich heterogeneities during converting.

Giving medicine the protection it deserves: Valor® packaging is the ultimate solution for all pharmaceutical filling environments. It is inherently strong and damage resistant, making it better able to withstand extreme events during pharmaceutical processing and field applications. These more robust containers also reduce down time due to glass-related interventions and provide enhanced protection for medicines in the hands of end users.

This webinar will address: Fill-finish manufacturing capacity can be limited by glass-related issues such as breakage, jams, and tip-overs, leading to line stoppage and operator interventions Coated vial technology has been developed to address these historical limitations of glass packaging Coated vial technology enables improved manufacturing capacity through an increase in effective line speed and operational reliability at speeds of 600+ vpm This webinar originally aired as part of Pharmapack Europe 2021